First Copycat Biotech Drug Spurs $250B Obamacare Savings

[blacken700]

Source: Forbes

Bruce Japsen

The first U.S. approval of the “generic” biologic prescription version of the widely prescribed anti-infective cancer medicine Neupogen officially opens the door to a new era in cheaper drugs that could save the U.S. health care system tens of billions of dollars a year.

The so-called biosimilar of Neupogen known as Zarxio from Novartis (NVS), was approved Friday by the Food and Drug Administration. Here’s Forbes’ David Kroll’s look at the approval.

Zarxio’s expected to be prescribed as a cheaper alternative to a brand name drug sold by Amgen (AMGN) that had an average monthly price of $3,500, according to pharmacy benefit manager Express Scripts (ESRX).

Biosimilars are possible thanks to the Affordable Care Act and the law’s promise to bring cheaper versions of expensive biotech drugs to the U.S. market.

FULL story at link.


Read more: http://www.forbes.com/sites/brucejapsen/2015/03/07/first-copycat-biotech-drug-spurs-250b-obamacare-savings/

[GigantorX]

Source: Forbes

Bruce Japsen

The first U.S. approval of the “generic” biologic prescription version of the widely prescribed anti-infective cancer medicine Neupogen officially opens the door to a new era in cheaper drugs that could save the U.S. health care system tens of billions of dollars a year.

The so-called biosimilar of Neupogen known as Zarxio from Novartis (NVS), was approved Friday by the Food and Drug Administration. Here’s Forbes’ David Kroll’s look at the approval.

Zarxio’s expected to be prescribed as a cheaper alternative to a brand name drug sold by Amgen (AMGN) that had an average monthly price of $3,500, according to pharmacy benefit manager Express Scripts (ESRX).

Biosimilars are possible thanks to the Affordable Care Act and the law’s promise to bring cheaper versions of expensive biotech drugs to the U.S. market.

FULL story at link.


Read more: http://www.forbes.com/sites/brucejapsen/2015/03/07/first-copycat-biotech-drug-spurs-250b-obamacare-savings/

 

Oh geeze, biosimilars  were coming to market whether the ACA was in place or not. They aren't "made possible" by a law and certainly not made possible by a terrible law and the "promise" (what does that even mean?) that it apparently made. 

Biosimilars/biologics and your standard pharmaceuticals were made possible by research, investments and risk taken by corporations (big and small) that saw a possible future and took a chance.

What a silly article based a totally fallacy.

[Soul Crusher]

Am paying THOUSANDS more a year due to GFYCARE.   F Obama - fng lying Kenyan communist post